The board of directors of the Company announced that Ascletis BioScience Co. Ltd. and Shanghai Roche Pharmaceuticals Ltd. completed the signing of an addendum agreement on September 16, 2022, pursuant to which the promotion services for Pegasys® (a pegylated interferon for treatment of Hepatitis B and C) provided by Ascletis BioScience to Roche Pharma China will be terminated with effect from December 31, 2022. The promotion service for Pegasys ® was started from December 2018 pursuant to the partnership agreement between Ascletis BioScience and Roche Pharma China dated November 20, 2018 (the "Partnership Agreement").

Under the Partnership Agreement, Ascletis BioScience was granted an exclusive marketing promotion right for promotion services of Pegasys® in Mainland China and in turn entitled to receive a certain percentage of the sales revenue as consideration. After a long-term and successful cooperation and based on the strategic adjustment made by Roche Pharma China with regard to Mainland China market, Ascletis BioScience and Roche Pharma China have agreed that the two parties will not continue the partnership for promotion of Pegasys® in Mainland China market with effect from December 31, 2022. Roche Pharma China will neither seek other partner, nor by itself, to conduct promotion of Pegasys® in Mainland China.